<DOC>
	<DOCNO>NCT00044772</DOCNO>
	<brief_summary>The primary objective determine efficacy , safety , tolerability venlafaxine extend release ( ER ) capsule treatment outpatient panic disorder ( PD ) comparison placebo .</brief_summary>
	<brief_title>Study Evaluating Venlafaxine ER Patients With Panic Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<criteria>Meet DSMIV criterion PD ( without agoraphobia ) least 3 month study day 1 Have sufficient symptom require anxiolytic drug therapy Have score â‰¥4 Clinical Global Impressions Scale ( CGI ) severity illness item screen baseline Known hypersensitivity venlafaxine ( IR ER ) , related compound , paroxetine History presence clinically important hepatic , renal , medical disease might compromise study detrimental patient ( eg , clinically important cardiac arrhythmia , unstable diabetes , carcinoma [ except basal cell epithelioma ] , uncontrolled hypertension ) Clinically important abnormality screen physical examination , vital sign , electrocardiogram ( ECG ) , laboratory test urine drug screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2009</verification_date>
	<keyword>Panic</keyword>
	<keyword>Disorder</keyword>
</DOC>